First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo . This is a first-in-human trial of this antibody. Materials and Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 we...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Whan Park, Neunggyu Park, Hukeun Lee, Sung Hee Hong, Song-Jae Lee, Seong-Won Song, Kyung Kim, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Do-Hyun Nam, Jeong-Won Lee, Keunchil Park, Kyoung-Mee Kim, Jeeyun Lee
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: SAGE Publishing 2020-06-01
Σειρά:Therapeutic Advances in Medical Oncology
Διαθέσιμο Online:https://doi.org/10.1177/1758835920926796
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια